Food Pathogen Testing Market by Product Type (Culture Methods, Immunoassays, Pcr Tests), Sample Type (Dairy, Fruits And Vegetables, Meat And Poultry), Pathogen Type, Methodology, End Users, Distribution - Global Forecast 2025-2032
Description
The Food Pathogen Testing Market was valued at USD 16.47 billion in 2024 and is projected to grow to USD 17.85 billion in 2025, with a CAGR of 8.51%, reaching USD 31.67 billion by 2032.
An urgent industry inflection moment where technological advances, regulatory pressures, and supply chain complexity converge to redefine food pathogen risk management
The increasing complexity of global food supply chains, combined with heightened regulatory scrutiny and evolving detection technologies, has refocused organizational priorities around pathogen testing. Food safety leaders face simultaneous pressure to accelerate detection times, validate novel methods, and maintain compliance with dynamic regulatory frameworks while preserving operational throughput and product integrity.
Advances in molecular diagnostics, automated laboratory workflows, and data analytics are changing how risk is managed across processing plants, distribution networks, and retail environments. These technological shifts intersect with cost considerations, talent availability, and the need for harmonized testing protocols. The result is a richer set of options for ensuring public health and brand protection, but also a more complex decision environment that demands clear criteria, rigorous validation, and cross-functional alignment between quality, operations, procurement, and R&D teams.
Converging technological advances, data integration, and stakeholder expectations are accelerating the transition from compliance testing to strategic pathogen surveillance
The landscape for food pathogen testing is undergoing transformative shifts driven by both scientific innovation and changing stakeholder expectations. Rapid methods have moved from validation projects to operational deployments, enabling shorter hold times and faster release decisions. Next-generation sequencing and high-resolution molecular tools have expanded the granularity of outbreak investigations and source attribution, while improvements in sample preparation and automation have increased throughput without a proportional rise in labor requirements.
Concurrently, digital integration is elevating the role of data in risk management. Cloud-enabled laboratory information management systems and analytics platforms support trending, anomaly detection, and regulatory reporting in near real time. Supply chain transparency expectations and consumer scrutiny are pushing companies to adopt more proactive testing strategies, and regulatory agencies are increasingly receptive to method equivalency where performance criteria are met. Together, these forces are shifting testing from a reactive compliance activity to a strategic capability that supports brand protection, operational efficiency, and faster response to contamination events.
How changes to US import levies in 2025 reshaped procurement, supplier strategies, and tactical decisions for laboratory instrumentation, reagents, and validation programs
The tariff environment established in the United States in 2025 has had a pronounced effect on procurement dynamics for laboratory equipment, consumables, and reagents used in pathogen testing. Organizations that relied heavily on imported instrumentation or single-source reagents found unit costs and lead times less predictable, compelling procurement and quality teams to reassess supplier portfolios and contractual terms. In many cases, this translated into an increased emphasis on multi-sourcing strategies, local distribution partnerships, and early inventory planning to mitigate disruption risks.
These tariff-driven shifts also influenced investment timing for capital equipment and validation programs. Some laboratories accelerated replacement cycles to secure preferred pricing before tariff changes took full effect, while others deferred non-critical purchases to preserve working capital. The policy environment prompted a renewed focus on supplier performance characterization, on-site spares inventory, and technical support arrangements. For organizations designing testing programs, the tariffs reinforced the strategic value of method standardization, in-house reagent formulation capabilities, and collaborative purchasing arrangements that can absorb cost volatility without compromising analytical integrity.
A layered segmentation framework revealing how product classes, sample matrices, pathogen biology, methodologies, end-user profiles, and distribution channels influence testing choices
A segmentation-led view of the industry clarifies where investments, validation effort, and operational shifts are concentrated. Based on Product Type, the landscape is examined across Culture Methods, Immunoassays, PCR Tests, and Sequencing; Culture Methods includes Enrichment Culture and Plate Culture, Immunoassays includes Enzyme Linked Immunosorbent Assay and Lateral Flow, PCR Tests includes Qualitative PCR and Quantitative PCR, and Sequencing includes Next Generation Sequencing and Sanger Sequencing. Each of these product categories carries distinct performance trade-offs: culture methods remain the regulatory backbone for certain confirmations, immunoassays deliver cost-effective screening, PCR modalities provide sensitivity and quantitation, and sequencing offers resolution for epidemiology and deep characterization.
When the analysis is framed Based on Sample Type, the research considers Dairy, Fruits And Vegetables, Meat And Poultry, Processed Foods, and Seafood; Dairy is broken down into Cheese, Milk, and Yogurt, Fruits And Vegetables into Fruits and Leafy Greens, Meat And Poultry into Beef, Pork, and Poultry, Processed Foods into Frozen and Ready To Eat, and Seafood into Fish and Shellfish. Sample matrix differences materially affect method selection, enrichment protocols, and validation complexity, with high-fat or complex matrices often requiring bespoke extraction and inhibitor-removal workflows to maintain assay performance.
Looking at Pathogen Type, the structure covers Campylobacter, Escherichia Coli, Listeria, and Salmonella; Campylobacter is further examined through Jejuni, Escherichia Coli through O157 H7, Listeria through Monocytogenes, and Salmonella through Enterica Serovar Typhimurium. Pathogen biology dictates both sampling strategy and analytical sensitivity requirements, and emerging variants or serotypes can necessitate periodic method updates and confirmatory sequencing work.
Methodology segmentation contrasts Conventional Methods and Rapid Methods; Conventional Methods encompasses Culture and Microscopy, while Rapid Methods incorporates Biosensors, Immunoassay, and Polymerase Chain Reaction. Rapid approaches accelerate decision timelines but require rigorous equivalency demonstration against conventional approaches to ensure regulatory and legal defensibility. Finally, the End Users axis differentiates Contract Testing Laboratories, Food Manufacturers, Regulatory Agencies, and Research Institutes, with Food Manufacturers further parsed into Large Manufacturers and Small Manufacturers, and Distribution is categorized into Direct Sales and Distribution Partners. Each end-user type has unique procurement cycles, validation capabilities, and technical staffing models, which in turn influence adoption rates and the types of commercial engagements that are most effective.
Taken together, these segmentation layers reveal where capability investments yield the greatest operational leverage, where validation resources must be concentrated, and how commercial models should be adapted to serve diverse laboratory sophistication and supply chain footprints.
How regional regulatory frameworks, infrastructure maturity, and supply chain characteristics in the Americas, Europe Middle East & Africa, and Asia-Pacific drive differentiated adoption pathways
Regional dynamics shape testing approaches and the pace of technology adoption, with each geographic area exhibiting distinct regulatory frameworks, infrastructure maturity, and supply chain characteristics. In the Americas, regulatory clarity and large-scale processing operations drive adoption of automated platforms and rapid methods, while private sector consolidation and contract laboratory networks create demand for scalable validation and support services. North American and South American differences emerge in logistics, cold-chain reliability, and domestic supplier ecosystems, which in turn affect procurement strategies and risk tolerance.
Across Europe, Middle East & Africa, divergent regulatory harmonization, trade agreements, and investment in public health laboratories create a mosaic of adoption patterns. Western European markets tend to emphasize traceability, rigorous method validation, and integration with national surveillance systems, whereas emerging markets in the Middle East & Africa often prioritize capacity building, training, and partnerships to expand basic testing infrastructure. Cross-border trade within the region further incentivizes alignment to recognized testing standards to facilitate market access.
The Asia-Pacific region combines hyper-competitive manufacturing ecosystems with rapidly modernizing laboratory networks. High-volume processing centers and extensive export-oriented supply chains make rapid detection and throughput critical, while increased domestic production of reagents and instrumentation offers potential resilience against import shocks. Regulatory modernization and active public-private collaborations are accelerating adoption in several Asia-Pacific markets, but heterogeneity in laboratory accreditation and workforce skill levels continues to shape implementation timelines and support requirements.
Competitive dynamics driven by integrated service offerings, global support footprints, and strategic partnerships to accelerate validation and scale across complex food systems
The competitive landscape features a mix of established diagnostics manufacturers, specialized sequencing and molecular providers, contract testing networks, and niche biosensor innovators. Market participants are increasingly defined less by product category and more by the breadth of end-to-end solutions they can offer, including validation support, method training, installation services, and integrated data platforms. Strategic partnerships between instrument providers and laboratory networks have become a common route to accelerate field validation and scale deployments while sharing the costs of service ecosystems.
Operational excellence, supply chain reliability, and regulatory engagement are key differentiators. Firms that invest in global service footprints, rapid spare-parts provisioning, and robust technical training programs tend to secure longer-term contracts with large manufacturers and contract labs. At the same time, specialized providers that focus on niche capabilities-such as high-throughput sequencing workflows, custom assay development, or food matrix-specific extraction kits-can command premium positioning where performance or resolution matters most. Consolidation and selective M&A activity have been observed as organizations seek to pair complementary capabilities, shorten time-to-market for innovations, and expand geographic reach.
Practical strategic and operational steps to strengthen laboratory resilience, diversify supply sources, and accelerate method validation for robust pathogen surveillance
Industry leaders should adopt a proactive portfolio of tactics to strengthen testing programs, mitigate supply risks, and deliver faster, more reliable outcomes. First, diversifying sources for critical reagents and components while qualifying alternate suppliers reduces single‑point failure risk and improves negotiating leverage. Second, prioritizing validation roadmaps that include both conventional and rapid methods ensures continuity of operations while enabling faster release decisions where appropriate. Investing in cross-training for laboratory staff and shared-service models across facilities increases resilience and reduces bottlenecks during peak demand or disruption.
Leaders should also accelerate digital integration by linking laboratory information systems with enterprise quality and supply chain platforms to enable timely decision-making and trend analysis. Collaborative arrangements with external laboratories, academic centers, and public health authorities can augment internal capabilities for outbreak investigations and sequencing-based attribution. Finally, aligning procurement, legal, and regulatory affairs teams to develop tariff mitigation strategies, long-term supply agreements, and contingency inventory plans will help stabilize unit costs and reduce exposure to sudden policy shifts. Taken together, these actions deliver a defensible testing posture that balances speed, accuracy, and cost-effectiveness.
A rigorous mixed-methods approach combining stakeholder interviews, laboratory walkthroughs, method comparisons, regulatory review, and triangulated evidence for operational credibility
The research underpinning this report used a mixed-methods approach to ensure technical rigor and practical relevance. Primary inputs included structured interviews with laboratory directors, quality assurance leaders, procurement specialists, and regulatory officials, supplemented by technical walkthroughs of laboratory workflows and vendor validations to observe real-world implementation challenges. Laboratory-level performance characteristics were reviewed through method comparison studies and peer-reviewed literature to ensure analytical assertions align with current scientific consensus.
Secondary research encompassed standards and guidance documents from relevant regulatory bodies, trade and supply chain analyses, and a targeted review of technology roadmaps for diagnostics, sequencing, and automation. Data synthesis prioritized triangulation across multiple sources to reduce bias and surface robust insights. Throughout the process, quality controls were applied to documentation, including audit trails for interview inputs, a transparent assumptions log for interpretive conclusions, and expert review cycles to validate methodological soundness and relevance for operational decision-makers.
A clear operational imperative to integrate rapid technologies, supplier resilience, and data-driven quality systems to protect public health and commercial continuity
Food pathogen testing is at an inflection point where technological capability, regulatory expectations, and supply chain resilience intersect to create both opportunities and responsibilities for industry stakeholders. Organizations that invest in validation, diversify supplier relationships, and align data systems across the enterprise will be better positioned to reduce risk, accelerate recall avoidance, and protect brand value. Rapid methods and sequencing are not mere adjuncts to conventional approaches; when integrated thoughtfully they become strategic levers that enhance situational awareness and shorten response cycles.
The path forward requires disciplined execution. Leaders must balance near-term operational needs with longer-term capability building, ensuring that investments in automation, staff development, and digital infrastructure are coupled with robust quality assurance and regulatory engagement. By adopting a systematic approach to segmentation, regional dynamics, and supplier risk, organizations can design resilient testing programs that support public health objectives and commercial continuity.
Note: PDF & Excel + Online Access - 1 Year
An urgent industry inflection moment where technological advances, regulatory pressures, and supply chain complexity converge to redefine food pathogen risk management
The increasing complexity of global food supply chains, combined with heightened regulatory scrutiny and evolving detection technologies, has refocused organizational priorities around pathogen testing. Food safety leaders face simultaneous pressure to accelerate detection times, validate novel methods, and maintain compliance with dynamic regulatory frameworks while preserving operational throughput and product integrity.
Advances in molecular diagnostics, automated laboratory workflows, and data analytics are changing how risk is managed across processing plants, distribution networks, and retail environments. These technological shifts intersect with cost considerations, talent availability, and the need for harmonized testing protocols. The result is a richer set of options for ensuring public health and brand protection, but also a more complex decision environment that demands clear criteria, rigorous validation, and cross-functional alignment between quality, operations, procurement, and R&D teams.
Converging technological advances, data integration, and stakeholder expectations are accelerating the transition from compliance testing to strategic pathogen surveillance
The landscape for food pathogen testing is undergoing transformative shifts driven by both scientific innovation and changing stakeholder expectations. Rapid methods have moved from validation projects to operational deployments, enabling shorter hold times and faster release decisions. Next-generation sequencing and high-resolution molecular tools have expanded the granularity of outbreak investigations and source attribution, while improvements in sample preparation and automation have increased throughput without a proportional rise in labor requirements.
Concurrently, digital integration is elevating the role of data in risk management. Cloud-enabled laboratory information management systems and analytics platforms support trending, anomaly detection, and regulatory reporting in near real time. Supply chain transparency expectations and consumer scrutiny are pushing companies to adopt more proactive testing strategies, and regulatory agencies are increasingly receptive to method equivalency where performance criteria are met. Together, these forces are shifting testing from a reactive compliance activity to a strategic capability that supports brand protection, operational efficiency, and faster response to contamination events.
How changes to US import levies in 2025 reshaped procurement, supplier strategies, and tactical decisions for laboratory instrumentation, reagents, and validation programs
The tariff environment established in the United States in 2025 has had a pronounced effect on procurement dynamics for laboratory equipment, consumables, and reagents used in pathogen testing. Organizations that relied heavily on imported instrumentation or single-source reagents found unit costs and lead times less predictable, compelling procurement and quality teams to reassess supplier portfolios and contractual terms. In many cases, this translated into an increased emphasis on multi-sourcing strategies, local distribution partnerships, and early inventory planning to mitigate disruption risks.
These tariff-driven shifts also influenced investment timing for capital equipment and validation programs. Some laboratories accelerated replacement cycles to secure preferred pricing before tariff changes took full effect, while others deferred non-critical purchases to preserve working capital. The policy environment prompted a renewed focus on supplier performance characterization, on-site spares inventory, and technical support arrangements. For organizations designing testing programs, the tariffs reinforced the strategic value of method standardization, in-house reagent formulation capabilities, and collaborative purchasing arrangements that can absorb cost volatility without compromising analytical integrity.
A layered segmentation framework revealing how product classes, sample matrices, pathogen biology, methodologies, end-user profiles, and distribution channels influence testing choices
A segmentation-led view of the industry clarifies where investments, validation effort, and operational shifts are concentrated. Based on Product Type, the landscape is examined across Culture Methods, Immunoassays, PCR Tests, and Sequencing; Culture Methods includes Enrichment Culture and Plate Culture, Immunoassays includes Enzyme Linked Immunosorbent Assay and Lateral Flow, PCR Tests includes Qualitative PCR and Quantitative PCR, and Sequencing includes Next Generation Sequencing and Sanger Sequencing. Each of these product categories carries distinct performance trade-offs: culture methods remain the regulatory backbone for certain confirmations, immunoassays deliver cost-effective screening, PCR modalities provide sensitivity and quantitation, and sequencing offers resolution for epidemiology and deep characterization.
When the analysis is framed Based on Sample Type, the research considers Dairy, Fruits And Vegetables, Meat And Poultry, Processed Foods, and Seafood; Dairy is broken down into Cheese, Milk, and Yogurt, Fruits And Vegetables into Fruits and Leafy Greens, Meat And Poultry into Beef, Pork, and Poultry, Processed Foods into Frozen and Ready To Eat, and Seafood into Fish and Shellfish. Sample matrix differences materially affect method selection, enrichment protocols, and validation complexity, with high-fat or complex matrices often requiring bespoke extraction and inhibitor-removal workflows to maintain assay performance.
Looking at Pathogen Type, the structure covers Campylobacter, Escherichia Coli, Listeria, and Salmonella; Campylobacter is further examined through Jejuni, Escherichia Coli through O157 H7, Listeria through Monocytogenes, and Salmonella through Enterica Serovar Typhimurium. Pathogen biology dictates both sampling strategy and analytical sensitivity requirements, and emerging variants or serotypes can necessitate periodic method updates and confirmatory sequencing work.
Methodology segmentation contrasts Conventional Methods and Rapid Methods; Conventional Methods encompasses Culture and Microscopy, while Rapid Methods incorporates Biosensors, Immunoassay, and Polymerase Chain Reaction. Rapid approaches accelerate decision timelines but require rigorous equivalency demonstration against conventional approaches to ensure regulatory and legal defensibility. Finally, the End Users axis differentiates Contract Testing Laboratories, Food Manufacturers, Regulatory Agencies, and Research Institutes, with Food Manufacturers further parsed into Large Manufacturers and Small Manufacturers, and Distribution is categorized into Direct Sales and Distribution Partners. Each end-user type has unique procurement cycles, validation capabilities, and technical staffing models, which in turn influence adoption rates and the types of commercial engagements that are most effective.
Taken together, these segmentation layers reveal where capability investments yield the greatest operational leverage, where validation resources must be concentrated, and how commercial models should be adapted to serve diverse laboratory sophistication and supply chain footprints.
How regional regulatory frameworks, infrastructure maturity, and supply chain characteristics in the Americas, Europe Middle East & Africa, and Asia-Pacific drive differentiated adoption pathways
Regional dynamics shape testing approaches and the pace of technology adoption, with each geographic area exhibiting distinct regulatory frameworks, infrastructure maturity, and supply chain characteristics. In the Americas, regulatory clarity and large-scale processing operations drive adoption of automated platforms and rapid methods, while private sector consolidation and contract laboratory networks create demand for scalable validation and support services. North American and South American differences emerge in logistics, cold-chain reliability, and domestic supplier ecosystems, which in turn affect procurement strategies and risk tolerance.
Across Europe, Middle East & Africa, divergent regulatory harmonization, trade agreements, and investment in public health laboratories create a mosaic of adoption patterns. Western European markets tend to emphasize traceability, rigorous method validation, and integration with national surveillance systems, whereas emerging markets in the Middle East & Africa often prioritize capacity building, training, and partnerships to expand basic testing infrastructure. Cross-border trade within the region further incentivizes alignment to recognized testing standards to facilitate market access.
The Asia-Pacific region combines hyper-competitive manufacturing ecosystems with rapidly modernizing laboratory networks. High-volume processing centers and extensive export-oriented supply chains make rapid detection and throughput critical, while increased domestic production of reagents and instrumentation offers potential resilience against import shocks. Regulatory modernization and active public-private collaborations are accelerating adoption in several Asia-Pacific markets, but heterogeneity in laboratory accreditation and workforce skill levels continues to shape implementation timelines and support requirements.
Competitive dynamics driven by integrated service offerings, global support footprints, and strategic partnerships to accelerate validation and scale across complex food systems
The competitive landscape features a mix of established diagnostics manufacturers, specialized sequencing and molecular providers, contract testing networks, and niche biosensor innovators. Market participants are increasingly defined less by product category and more by the breadth of end-to-end solutions they can offer, including validation support, method training, installation services, and integrated data platforms. Strategic partnerships between instrument providers and laboratory networks have become a common route to accelerate field validation and scale deployments while sharing the costs of service ecosystems.
Operational excellence, supply chain reliability, and regulatory engagement are key differentiators. Firms that invest in global service footprints, rapid spare-parts provisioning, and robust technical training programs tend to secure longer-term contracts with large manufacturers and contract labs. At the same time, specialized providers that focus on niche capabilities-such as high-throughput sequencing workflows, custom assay development, or food matrix-specific extraction kits-can command premium positioning where performance or resolution matters most. Consolidation and selective M&A activity have been observed as organizations seek to pair complementary capabilities, shorten time-to-market for innovations, and expand geographic reach.
Practical strategic and operational steps to strengthen laboratory resilience, diversify supply sources, and accelerate method validation for robust pathogen surveillance
Industry leaders should adopt a proactive portfolio of tactics to strengthen testing programs, mitigate supply risks, and deliver faster, more reliable outcomes. First, diversifying sources for critical reagents and components while qualifying alternate suppliers reduces single‑point failure risk and improves negotiating leverage. Second, prioritizing validation roadmaps that include both conventional and rapid methods ensures continuity of operations while enabling faster release decisions where appropriate. Investing in cross-training for laboratory staff and shared-service models across facilities increases resilience and reduces bottlenecks during peak demand or disruption.
Leaders should also accelerate digital integration by linking laboratory information systems with enterprise quality and supply chain platforms to enable timely decision-making and trend analysis. Collaborative arrangements with external laboratories, academic centers, and public health authorities can augment internal capabilities for outbreak investigations and sequencing-based attribution. Finally, aligning procurement, legal, and regulatory affairs teams to develop tariff mitigation strategies, long-term supply agreements, and contingency inventory plans will help stabilize unit costs and reduce exposure to sudden policy shifts. Taken together, these actions deliver a defensible testing posture that balances speed, accuracy, and cost-effectiveness.
A rigorous mixed-methods approach combining stakeholder interviews, laboratory walkthroughs, method comparisons, regulatory review, and triangulated evidence for operational credibility
The research underpinning this report used a mixed-methods approach to ensure technical rigor and practical relevance. Primary inputs included structured interviews with laboratory directors, quality assurance leaders, procurement specialists, and regulatory officials, supplemented by technical walkthroughs of laboratory workflows and vendor validations to observe real-world implementation challenges. Laboratory-level performance characteristics were reviewed through method comparison studies and peer-reviewed literature to ensure analytical assertions align with current scientific consensus.
Secondary research encompassed standards and guidance documents from relevant regulatory bodies, trade and supply chain analyses, and a targeted review of technology roadmaps for diagnostics, sequencing, and automation. Data synthesis prioritized triangulation across multiple sources to reduce bias and surface robust insights. Throughout the process, quality controls were applied to documentation, including audit trails for interview inputs, a transparent assumptions log for interpretive conclusions, and expert review cycles to validate methodological soundness and relevance for operational decision-makers.
A clear operational imperative to integrate rapid technologies, supplier resilience, and data-driven quality systems to protect public health and commercial continuity
Food pathogen testing is at an inflection point where technological capability, regulatory expectations, and supply chain resilience intersect to create both opportunities and responsibilities for industry stakeholders. Organizations that invest in validation, diversify supplier relationships, and align data systems across the enterprise will be better positioned to reduce risk, accelerate recall avoidance, and protect brand value. Rapid methods and sequencing are not mere adjuncts to conventional approaches; when integrated thoughtfully they become strategic levers that enhance situational awareness and shorten response cycles.
The path forward requires disciplined execution. Leaders must balance near-term operational needs with longer-term capability building, ensuring that investments in automation, staff development, and digital infrastructure are coupled with robust quality assurance and regulatory engagement. By adopting a systematic approach to segmentation, regional dynamics, and supplier risk, organizations can design resilient testing programs that support public health objectives and commercial continuity.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid on-site CRISPR-based assays for real-time detection of foodborne pathogens
- 5.2. Integration of blockchain technology for end-to-end traceability in pathogen testing
- 5.3. Adoption of lab-on-a-chip microfluidic systems for portable food pathogen screening
- 5.4. Expansion of multiplex PCR platforms enabling simultaneous detection of multiple pathogens
- 5.5. Integration of AI-driven predictive analytics to anticipate contamination hotspots
- 5.6. Growing use of next-generation sequencing for comprehensive microbial risk profiling
- 5.7. Rising demand for accredited third-party testing to meet stringent regulatory standards
- 5.8. Implementation of immunoassay-based lateral flow tests for rapid pathogen identification
- 5.9. Development of automated high-throughput robotic systems for sample preparation and analysis
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Food Pathogen Testing Market, by Product Type
- 8.1. Culture Methods
- 8.1.1. Enrichment Culture
- 8.1.2. Plate Culture
- 8.2. Immunoassays
- 8.2.1. Enzyme Linked Immunosorbent Assay
- 8.2.2. Lateral Flow
- 8.3. Pcr Tests
- 8.3.1. Qualitative Pcr
- 8.3.2. Quantitative Pcr
- 8.4. Sequencing
- 8.4.1. Next Generation Sequencing
- 8.4.2. Sanger Sequencing
- 9. Food Pathogen Testing Market, by Sample Type
- 9.1. Dairy
- 9.1.1. Cheese
- 9.1.2. Milk
- 9.1.3. Yogurt
- 9.2. Fruits And Vegetables
- 9.2.1. Fruits
- 9.2.2. Leafy Greens
- 9.3. Meat And Poultry
- 9.3.1. Beef
- 9.3.2. Pork
- 9.3.3. Poultry
- 9.4. Processed Foods
- 9.4.1. Frozen
- 9.4.2. Ready To Eat
- 9.5. Seafood
- 9.5.1. Fish
- 9.5.2. Shellfish
- 10. Food Pathogen Testing Market, by Pathogen Type
- 10.1. Campylobacter
- 10.2. Escherichia Coli
- 10.3. Listeria
- 10.4. Salmonella
- 11. Food Pathogen Testing Market, by Methodology
- 11.1. Conventional Methods
- 11.1.1. Culture
- 11.1.2. Microscopy
- 11.2. Rapid Methods
- 11.2.1. Biosensors
- 11.2.2. Immunoassay
- 11.2.3. Polymerase Chain Reaction
- 12. Food Pathogen Testing Market, by End Users
- 12.1. Contract Testing Laboratories
- 12.2. Food Manufacturers
- 12.2.1. Large Manufacturers
- 12.2.2. Small Manufacturers
- 12.3. Regulatory Agencies
- 12.4. Research Institutes
- 13. Food Pathogen Testing Market, by Distribution
- 13.1. Direct Sales
- 13.2. Distribution Partners
- 14. Food Pathogen Testing Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Food Pathogen Testing Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Food Pathogen Testing Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. 3M Company
- 17.3.2. Agilent Technologies, Inc.
- 17.3.3. Bio-Rad Laboratories, Inc.
- 17.3.4. bioMérieux SA
- 17.3.5. Charles River Laboratories International, Inc.
- 17.3.6. Intertek Group PLC
- 17.3.7. John Bean Technologies
- 17.3.8. Merck KGaA
- 17.3.9. Mérieux NutriSciences Corporation
- 17.3.10. Microbac Laboratories, Inc.
- 17.3.11. Neogen Corporation
- 17.3.12. Nova Biologicals by Tentamus Group GmbH
- 17.3.13. Primus Group, Inc.
- 17.3.14. Q Laboratories
- 17.3.15. QIAGEN N.V.
- 17.3.16. RapidBio Systems, Inc.
- 17.3.17. SGS Société Générale de Surveillance SA
- 17.3.18. Symbio Laboratories
- 17.3.19. Thermo Fisher Scientific Inc.
- 17.3.20. TÜV Nord Group
- 17.3.21. Waters Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
